News | July 10, 2022
Capnopharm to acquire operational assets of Capnomed
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Tislelizumab is now approved in nine indications in China
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The medicine is now approved for eight indications across five different types of cancer in China.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
